Topic: Ucsd

Researchers at UC San Diego are investigating "COVID rebound" in patients taking Pfizer's Paxlovid, suggesting that current dosing may be insufficient. This has led to calls for adjusted treatment plans and higher dosages. Simultaneously, there is a renewed push for nasal vaccines, which some studies suggest provide better protection against infection than traditional injections.

Medical experts in San Diego, including doctors from Sharp and UCSD, warn of a "surge on a surge" as the Omicron variant begins to spread following the Thanksgiving holidays. Officials project that Omicron will become the dominant strain within weeks, potentially overwhelming local hospital capacity.